Journal article

Comparison of Bone and Renal Effects In HIV-infected Adults Switching to Abacavir or Tenofovir Based Therapy in a Randomized Trial

Thomas A Rasmussen, Danny Jensen, Martin Tolstrup, Ulla S Nielsen, Erland J Erlandsen, Henrik Birn, Lars Ostergaard, Bente L Langdahl, Alex L Laursen

PLoS ONE | PUBLIC LIBRARY SCIENCE | Published : 2012

University of Melbourne Researchers

Grants

Funding Acknowledgements

The study was supported by a grant of US$ 9,100 from GlaxoSmithKline (www.gsk.com). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.The study was supported by a grant of US$ 9,100 from GlaxoSmithKline (www.gsk.com). Lars Ostergaard has received consultancy and speaker's fee from: Abbott, MSD, Pfizer, Bristol-Meyer Squibb, GlaxoSmithKline, ViiV Healthcare, Gilead, and Tibotec. Alex L Laursen has served on the advisory board for GlaxoSmithKline, Gilead, and Janssen. Lamivudine/zidovudine and abacavir/lamivudine are manufactured by GSK; tenofovir/emtricitabine is manufactured by Gilead. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.